Update in Women's Health: Evidence Published in 2013
Authors: Janet P. Pregler, Carolyn J. Crandall
Journal: Annals of Internal Medicine (2014)

Updates6 May 2014Update in Women's Health: Evidence Published in 2013Janet P. Pregler, MD and Carolyn J. Crandall, MD, MSJanet P. Pregler, MDFrom the Iris Cantor–UCLA Women's Health Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.Search for more papers by this author and Carolyn J. Crandall, MD, MSFrom the Iris Cantor–UCLA Women's Health Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M14-0257 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This update summarizes 10 important studies published in 2013 that can change clinical practice. The authors reviewed articles relevant to sex- and gender-based differences in the care of women, defined as research on diseases and conditions more common in women or unique to women and on diseases and conditions in which the approach to care may be different for women. A major theme of research results is the importance of individualizing counseling, screening, and treatment strategies on the basis of patient characteristics.Breast CancerContinuing Adjuvant Tamoxifen Treatment for 10 Years Reduced Recurrence and Increased Survival in Women With Estrogen ...References1. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, et al; American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-96. [PMID: 20625130] CrossrefMedlineGoogle Scholar2. Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer [Abstract].. J Clin Oncol. 2013;31:Abstract 5. CrossrefGoogle Scholar3. American College of Radiology. ACR offers resources to physicians on breast density notification. 4 October 2013. Accessed at www.acr.org/Advocacy/eNews/20131004-Issue/ACR-Offers-Resources-to-Physicians-on-Breast-Density-Notification on 16 November 2013. Google Scholar4. U.S. Preventive Services Task Force. Screening for breast cancer. Accessed at www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm on 11 January 2014. Google Scholar5. Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al; Breast Cancer Working Group of the Cancer Intervention and Surveillance Modeling Network. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151:738-47. [PMID: 19920274] LinkGoogle Scholar6. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. [PMID: 17392385] CrossrefMedlineGoogle Scholar7. Moyer VA; U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;:. [PMID: 24366376] LinkGoogle Scholar8. Mandelblatt JS, Sheppard VB, Neugut AI. Black-white differences in breast cancer outcomes among older Medicare beneficiaries: does systemic treatment matter? [Editorial]. JAMA. 2013;310:376-7. [PMID: 23917286] CrossrefMedlineGoogle Scholar9. Committee opinion no. 575: exposure to toxic environmental agents. Obstet Gynecol. 2013;122:931-5. [PMID: 24084567] CrossrefMedlineGoogle Scholar10. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880-91. [PMID: 22711081] LinkGoogle Scholar11. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-72. [PMID: 22422631] CrossrefMedlineGoogle Scholar12. ACOG Committee Opinion no. 565: Hormone therapy and heart disease. Obstet Gynecol. 2013;121:1407-10. [PMID: 23812486] CrossrefMedlineGoogle Scholar13. Moyer VA; U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158:47-54. [PMID: 23090711] LinkGoogle Scholar14. U.S. Food and Drug Administration. Highlights of prescribing information for Mirena IUD. Accessed at www.accessdata.fda.gov/drugsatfda_docs/label/2009/021225s027lbl.pdf on 20 January 2014. Google Scholar15. U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;154:356-64. [PMID: 21242341] LinkGoogle Scholar16. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, et al; Study of Osteoporotic Fractures Research Group. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366:225-33. [PMID: 22256806] CrossrefMedlineGoogle Scholar17. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643-6. [PMID: 14576434] CrossrefMedlineGoogle Scholar18. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967-75. [PMID: 20810374] CrossrefMedlineGoogle Scholar19. Meador KJ, Loring DW. Risks of in utero exposure to valproate [Editorial]. JAMA. 2013;309:1730-1. [PMID: 23613078] CrossrefMedlineGoogle Scholar20. U.S. Food and Drug Administration. FDA Drug Safety Communication. Valproate anti-seizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. 6 May 2013. Accessed at www.fda.gov/Drugs/DrugSafety/ucm350684.htm on 11 January 2014. Google Scholar21. Cnattingius S, Villamor E, Johansson S, Edstedt Bonamy AK, Persson M, Wikström AK, et al. Maternal obesity and risk of preterm delivery. JAMA. 2013;309:2362-70. [PMID: 23757084] CrossrefMedlineGoogle Scholar22. Kjær MM, Lauenborg J, Breum BM, Nilas L. The risk of adverse pregnancy outcome after bariatric surgery: a nationwide register-based matched cohort study. Am J Obstet Gynecol. 2013;208:464.e1-5. [PMID: 23467053] CrossrefMedlineGoogle Scholar23. Maggard MA, Yermilov I, Li Z, Maglione M, Newberry S, Suttorp M, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA. 2008;300:2286-96. [PMID: 19017915] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From the Iris Cantor–UCLA Women's Health Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.Acknowledgment: The authors thank Patricia Ganz, MD; Zhao Ping Li, MD, PhD; Ilana Cass, MD; Angela Chen, MD; and Arleen Brown, MD, PhD, for critiques of parts of this work.Grant Support: By the Michael Parr Fund for Women's Health Research and Education, and the Executive Advisory Board of the Iris Cantor–UCLA Women's Health Center. Dr. Crandall received additional funding from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-0257.Corresponding Author: Janet P. Pregler, MD, Iris Cantor–UCLA Women's Health Center, 100 UCLA Medical Plaza, Suite 250, Los Angeles, CA 90095; e-mail, [email protected]ucla.edu.Current Author Addresses: Drs. Pregler and Crandall: Iris Cantor–UCLA Women's Health Center, 100 UCLA Medical Plaza, Suite 250, Los Angeles, CA 90095.Author Contributions: Conception and design: J.P. Pregler, C.J. Crandall.Analysis and interpretation of the data: C.J. Crandall.Drafting of the article: J.P. Pregler, C.J. Crandall.Critical revision of the article for important intellectual content: J.P. Pregler, C.J. Crandall.Final approval of the article: J.P. Pregler, C.J. Crandall.Obtaining of funding: J.P. Pregler.Administrative, technical, or logistic support: J.P. Pregler.This article was published online first at www.annals.org on 10 April 2014. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 6 May 2014Volume 160, Issue 9Page: 627-633KeywordsBariatric surgeryBirthBreast cancerEstrogensHormonesHuman papillomavirusMammographyPregnancy ePublished: 6 May 2014 Issue Published: 6 May 2014 CopyrightCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...